Delivery Order SPE2DB20D9136-SPE2DB26FJ58E
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency on September 17, 2025, for Xolair 150 mg/mL syringes, with a ceiling value of $1,547.40. This firm fixed-price delivery order is part of DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at approximately $500 million and valid through November...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order by the Defense Logistics Agency (DLA) for Xolair 150 mg/ml syringes, valued at $11,605.50. This firm fixed-price delivery order, issued on September 23, 2025, with an ultimate completion date of October 15, 2025, represents a direct procurement without set-aside designation. The award is issued under DMS Pharmaceutical Group's existing...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency for 150 mg/ml Xolair syringes valued at $1,547.40. This firm fixed-price delivery order, issued on September 26, 2025, with an ultimate completion date of October 20, 2025, represents a specific pharmaceutical product requisition issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA....
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order by the Defense Logistics Agency (DLA) for Xolair 150 mg/ml syringes with a ceiling value of $21,276.75. This firm fixed-price delivery order, issued on September 18, 2025, is expected to be completed by October 9, 2025. The award represents a specific procurement action executed under DMS Pharmaceutical Group's larger Indefinite Delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a firm fixed-price delivery order valued at $5,581.44 by the Defense Logistics Agency (DLA) for the supply of Xolair 300 mg/2 ml syringes. The delivery order, issued on September 10, 2025, carries an ultimate completion date of October 1, 2025, with no set-aside designation applied. This award represents a specific task order issued under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a $9,284.40 firm fixed-price delivery order from the Defense Logistics Agency (DLA) on September 24, 2025, for XOLAIR 150 mg/ml syringes. The award, which carries no set-aside designation, is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499.999 billion vehicle valid through November 2026 that enables...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $3,094.80 by the Defense Logistics Agency on August 27, 2025, for the supply of Xolair 150 mg/ml syringes. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of September 18, 2025, and carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger single-award...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $37,137.60 by the Defense Logistics Agency on September 23, 2025, for the supply of Xolair 150 mg/ml syringes. The contract employs firm fixed-price pricing with an ultimate completion date of October 15, 2025, and was awarded without set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a firm fixed-price delivery order valued at $2,321.10 for Xolair 150 mg/ml syringes by the Defense Logistics Agency's Medical Supply Chain. The contract, issued on September 23, 2025, with an ultimate completion date of October 15, 2025, carries no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's existing Indefinite Delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a firm fixed-price delivery order valued at $1,712.22 by the Defense Logistics Agency (DLA) for the supply of Xolair 150 mg/ml auto-injectors. The delivery order, issued on September 12, 2025, with an ultimate completion date of October 3, 2025, carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger Indefinite Delivery...
- SPE2DB20D9136Indefinite Delivery Contract
- SPE2DB20D9136-SPE2DB26FJ58EDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on October 14, 2025, for Xolair 150 mg/mL syringes, with a ceiling value of $6,189.60 and an ultimate completion date of November 4, 2025. This delivery order does not include a set-aside designation and represents a specific product request issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at $499.9 million and valid through November 2026. Xolair (omalizumab) is a monoclonal antibody therapy used in the treatment of allergic asthma and chronic urticaria, making this award consistent with the company's extensive portfolio of specialty pharmaceutical products supplied to Department of Defense healthcare facilities. The award reflects DMS Pharmaceutical Group's established role as a critical supplier within the federal pharmaceutical supply chain, leveraging its woman-owned small business status to compete effectively in federal procurement markets. The DLA's SPE2DB program provides a streamlined mechanism for procuring a comprehensive range of pharmaceutical items—including branded and generic prescription drugs, biologics, and specialty medications—to support medical supply needs across military health facilities nationwide. This delivery order exemplifies the operational efficiency of the indefinite delivery vehicle, enabling the government to obtain specialized pharmaceutical products with rapid fulfillment timelines while maintaining firm fixed pricing.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.2k | 10/14/25 |